There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
More than 120 speakers and 5,000 delegates are expected to attend
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA
Subscribe To Our Newsletter & Stay Updated
